Rentschler Biopharma SE

Rentschler in Collaboration to Improve AAV-Manufacturing for Gene Therapies

German CDMO Rentschler Biopharma is collaborating with the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organization specializing in the advancement of cell and gene therapies, and Oxford-based mass photometry specialist Refeyn, to improve the manufacturing adeno-associated viruses (AAVs).

Rentschler Invests in UK Cell and Gene Therapy Site

German CDMO Rentschler Biopharma is to establish manufacturing capacity for advanced therapy medicinal products (ATMPs), including Adeno-associated virus (AAV) vectors for clinical trials, at the Cell and Gene Therapy Catapult (CGT) site in Stevenage, UK.

Optimal Time-to-Market for Life-Saving Biopharmaceuticals

Rentschler Biopharma offers bioprocess development and cGMP manufacturing for high-quality biopharmaceuticals. The company’s strength lies in its extensive experience with complex proteins and exceptional track record of over 100 different therapeutic protein formats.

Rentschler to Support BioNTech-Pfizer Vaccine

German CDMO Rentschler Biopharma has reached agreement with Pfizer and BioNTech to handle the downstream purification process for the partnership’s mRNA-based COVID-19 vaccine. No price tag was disclosed for the deal that also calls for the CDMO to handle small-batch manufacturing for a range of BioNTech's other mRNA clinical-stage projects.

Outsourcing Services: from Gene to Patient

Rentschler Biopharma SE, headquartered in Laupheim, Germany, is a leading, family-owned, full-service biopharma CDMO. Owing to agile decision making and efficient processes, Rentschler Biopharma is the preferred outsourcing partner for bioprocess development, cGMP manufacturing, as well as elaboration of product approval strategies for over 150 clients worldwide.

Nikolaus F. Rentschler and Frank Mathias Awarded as "EY Entrepreneur of the Year"

Driving Innovation and Extending Its Global Reach

Last year, Rentschler Biopharma, a German contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced its "Strategy 2025."

Rentschler Biopharma Extends Japanese Pact

German biopharmaceuticals contract development and manufacturing organization Rentschler Biopharma is extending and deepening its existing collaboration in Japan with Summit Pharmaceuticals International (SPI), a wholly owned subsidiary of Sumitomo.

Rentschler Facility Wins ‘Facility of the Year Award’ 2012 in Equipment Innovation

Pharmaceutical Technology - The new manufacturing facility of German biotech company Rentschler has won the 2012 Facility of the Year Award (FOYA) in the category "Equipment Innovation" for its flexible, multi-product manufacturing facility designed to minimize manufacturing costs and product cycle times.